The winner of the Go Global Awards ‘Business of the Year – Category of Life Science’ was awarded to CanaQuest, by the International Trade Council Research & development.
Did you know our Partners, CanaQuest, won the prestigious ‘Business of the Year’ award? The final judging took place during the Think Global Conference on 22-23 October in Chicago. This recognition will further open doors for international business opportunities. CanaQuest presented before a select judging panel and an audience of CEOs, investors and Government Ministers and Ambassadors.
To view the presentation provided visit: http://nnw.fm/Go-Global-Awards-Presentation.
Did you know CanaQuest Medical Corp is a Partner of Medical Cannabis Network? Learn more about the company and their world of medical cannabis formulations.
The rise of CanaQuest
Recently, CanaQuest was granted a cannabis sales-import-export licence from Health Canada. Additionally, CanaQuest filed an international patent on its first game-changing formulation, Mentabinol™, which protects THC users from negative psychotic side effects.
The company is focused on the development of proprietary research and medical cannabis products utilising cannabis oil combined with other botanical extracts, including algae oil.
Positive data from CanaQuest’s research and preclinical trials has positioned the company to bring its first CBD and THC based products to market. The company has engaged two prestigious Canadian universities, Western University and the University of Waterloo, to provide research and to create these unique formulations and products.
The company’s research is focused on mitigation of the spread of cancerous tumours and the development of novel pharmacotherapies for mental health. The company has found a competitive advantage working with Dr Steve Laviolette, a scientific veteran with over 13 years of research experience in the field of mental health and cannabis, and his dedicated scientific team of 12 scientists at Western University.
This partnership gives the company a tremendous competitive advantage compared to sporadic publicly disclosed research in this area. The completed pre-clinical trials at the Western University lab have demonstrated exciting results.
“Safer and clinically superior cannabinoid formulations”
“We continue to be enthusiastic about our partnership with CanaQuest, and we are proud they are winners of the Go Global Awards ‘Business of the Year – Category of Life Science,’ states Laviolette.
“The results of our research have demonstrated safer and clinically superior cannabinoid formulations aimed at treating the symptoms of various mental disorders.” Paul Ramsay, Co-Founder and President of CanaQuest, adds.
“Being a winner of the Go Global Awards Business of the Year – category of Life Science, out of over 3,000 applications, is an honour and speaks highly of the tremendous accomplishments by Dr Steven Laviolette and his team.”
About CanaQuest Medical Corp
CanaQuest Medical Corp is a life science company focused on medical cannabis products. The company is committed to developing novel health products that utilise cannabis, hemp, and botanical extracts, including algae oils.
The company has engaged two prestigious Canadian universities to research and develop formulated products, which the company is in the process of launching. Our research is focused on the use of cannabis in the context of cancer and the use of cannabis derivatives for the development of our novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder (PTSD).
CanaQuest was awarded a cannabis sales-import-export license from Health Canada.
Additionally, CanaQuest filed an international patent on a first game changing discovery, Mentabinol™, protecting THC users from negative psychotic side effects. For more information, visit the CanaQuest website at http://www.canaquest.com
